Chromosomal alterations, prognostic factors, and targeted molecular therapies for malignant meningiomas

Journal of Clinical Neuroscience

Volumn 20, Issue 1, 2013, Pages 17-22

  Yew, Andrew ^a   Trang, Andy ^a   Nagasawa, Daniel T ^a   Spasic, Marko ^a   Choy, Winward ^a   Garcia, Heather M ^a   Yang, Isaac ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Malignant meningioma; Molecular therapies; Prognostic factors

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; HYDROXYUREA; IMATINIB; KI 67 ANTIGEN; MIFEPRISTONE; NELFINAVIR; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR BB; PROGESTERONE RECEPTOR; PROTEIN KINASE B; RECOMBINANT ALPHA2B INTERFERON; SEMAPHORIN 3A; SOMATOSTATIN; SUNITINIB; TAMOXIFEN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR HES 1; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; MALIGNANT MENINGIOMA; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; TUMOR VOLUME; WNT SIGNALING PATHWAY;

CHROMOSOME ABERRATIONS; HUMANS; INTERFERON-ALPHA; KI-67 ANTIGEN; MAGNETIC RESONANCE IMAGING; MENINGEAL NEOPLASMS; MENINGIOMA; MOLECULAR TARGETED THERAPY; PROGNOSIS; RECEPTORS, PITUITARY HORMONE;

EID: 84871407367     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2012.02.007     Document Type: Review

References (85)

1. W. Choy, W. Kim, and D. Nagasawa The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments Neurosurg Focus 30 2011 E6
2. P.Y. Wen, E. Quant, and J. Drappatz Medical therapies for meningiomas J Neurooncol 99 2010 365 378
3. C. Lopez-Gines, R. Gil-Benso, and M. Collado-Diaz Meningioma: a model of cytogenetic evolution in tumoral initiation and progresion Neurocirugia (Astur) 14 2003 517 525 (Pubitemid 38019957)
4. K.D. Zang Meningioma: a cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases Cytogenet Cell Genet 93 2001 207 220 (Pubitemid 32799806)
5. R.G. Weber, J. Bostrom, and M. Wolter Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression Proc Natl Acad Sci U S A 94 1997 14719 14724 (Pubitemid 28041440)
6. Y. Liu, J.C. Pang, and S. Dong Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas Hum Pathol 36 2005 416 425 (Pubitemid 40591813)
7. C. Mawrin, and A. Perry Pathological classification and molecular genetics of meningiomas J Neurooncol 99 2010 379 391
8. R. Buschges, K. Ichimura, and R.G. Weber Allelic gain and amplification on the long arm of chromosome 17 in anaplastic meningiomas Brain Pathol 12 2002 145 153 (Pubitemid 34259916)
9. K. Lamszus, U. Lengler, and N.O. Schmidt Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy Neurosurgery 46 2000 938 947 [discussion 947-948]
10. K. Lamszus Meningioma pathology, genetics, and biology J Neuropathol Exp Neurol 63 2004 275 286 (Pubitemid 38429025)
11. L.A. Langford, M.A. Piatyszek, and R. Xu Telomerase activity in ordinary meningiomas predicts poor outcome Hum Pathol 28 1997 416 420 (Pubitemid 27175081)
12. M. Simon, T.W. Park, and S. Leuenroth Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression J Neurosurg 92 2000 832 840 (Pubitemid 30243932)
13. D.X. Cai, R. Banerjee, and B.W. Scheithauer Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications J Neuropathol Exp Neurol 60 2001 628 636 (Pubitemid 32523627)
14. A. Maillo, A. Orfao, and J.M. Sayagues New classification scheme for the prognostic stratification of meningioma on the basis of chromosome 14 abnormalities, patient age, and tumor histopathology J Clin Oncol 21 2003 3285 3295 (Pubitemid 46606262)
15. A. Perry, R. Banerjee, and C.M. Lohse A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas Brain Pathol 12 2002 183 190 (Pubitemid 34259920)
16. J. Bostrom, B. Meyer-Puttlitz, and M. Wolter Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas Am J Pathol 159 2001 661 669 (Pubitemid 32751096)
17. M.L. Falchetti, L.M. Larocca, and R. Pallini Telomerase in brain tumors Childs Nerv Syst 18 2002 112 117 (Pubitemid 36024316)
18. I. Laurendeau, M. Ferrer, and D. Garrido Gene expression profiling of the hedgehog signaling pathway in human meningiomas Mol Med 16 2010 262 270
19. M. Simon, A. von Deimling, and J.J. Larson Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression Cancer Res 55 1995 4696 4701
20. M.J. Riemenschneider, A. Perry, and G. Reifenberger Histological classification and molecular genetics of meningiomas Lancet Neurol 5 2006 1045 1054 (Pubitemid 44709980)
21. G.S. Baia, S. Stifani, and E.T. Kimura Notch activation is associated with tetraploidy and enhanced chromosomal instability in meningiomas Neoplasia 10 2008 604 612 (Pubitemid 351770304)
22. T. Iso, L. Kedes, and Y. Hamamori HES and HERP families: multiple effectors of the Notch signaling pathway J Cell Physiol 194 2003 237 255 (Pubitemid 36176887)
23. T. Harada, R.M. Irving, and J.H. Xuereb Molecular genetic investigation of the neurofibromatosis type 2 tumor suppressor gene in sporadic meningioma J Neurosurg 84 1996 847 851 (Pubitemid 26120100)
24. P. Merel, K. Hoang-Xuan, and M. Sanson Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas Genes Chromosomes Cancer 13 1995 211 216
25. A. Perry, D.H. Gutmann, and G. Reifenberger Molecular pathogenesis of meningiomas J Neurooncol 70 2004 183 202 (Pubitemid 39545731)
26. C. Mawrin, T. Sasse, and E. Kirches Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas Clin Cancer Res 11 2005 4074 4082 (Pubitemid 40791571)
27. D. Loussouarn, J. Brunon, and H. Avet-Loiseau Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study Hum Pathol 37 2006 415 421
28. D. Alexandru, M.J. Glantz, and L. Kim Pulmonary metastases in patients with recurrent, treatment-resistant meningioma: prognosis and identification by (111) indium-octreotide imaging Cancer 117 2011 4506 4511
29. M. Kallio, R. Sankila, and T. Hakulinen Factors affecting operative and excess long-term mortality in 935 patients with intracranial meningioma Neurosurgery 31 1992 2 12
30. R.O. Mirimanoff, D.E. Dosoretz, and R.M. Linggood Meningioma: analysis of recurrence and progression following neurosurgical resection J Neurosurg 62 1985 18 24 (Pubitemid 15199399)
31. M. Ohta, T. Iwaki, and T. Kitamoto MIB1 staining index and scoring of histologic features in meningioma. Indicators for the prediction of biologic potential and postoperative management Cancer 74 1994 3176 3189 (Pubitemid 24375075)
32. D. Simpson The recurrence of intracranial meningiomas after surgical treatment J Neurol Neurosurg Psychiatry 20 1957 22 39
33. T.W. Dziuk, S. Woo, and E.B. Butler Malignant meningioma: an indication for initial aggressive surgery and adjuvant radiotherapy J Neurooncol 37 1998 177 188 (Pubitemid 28073591)
34. S.Y. Yang, C.K. Park, and S.H. Park Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features J Neurol Neurosurg Psychiatry 79 2008 574 580
35. L. Palma, P. Celli, and C. Franco Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases J Neurosurg 86 1997 793 800 (Pubitemid 27187681)
36. A. Perry, B.W. Scheithauer, and S.L. Stafford "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications Cancer 85 1999 2046 2056 (Pubitemid 29202781)
37. A. Durand, F. Labrousse, and A. Jouvet WHO grade II and III meningiomas: a study of prognostic factors J Neurooncol 95 2009 367 375
38. E.B. Hug, A. Devries, and A.F. Thornton Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy J Neurooncol 48 2000 151 160
39. H.J. Marcus, S.J. Price, and M. Wilby Radiotherapy as an adjuvant in the management of intracranial meningiomas: are we practising evidence-based medicine? Br J Neurosurg 22 2008 520 528
40. D. Pasquier, S. Bijmolt, and T. Veninga Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the Rare Cancer Network Int J Radiat Oncol Biol Phys 71 2008 1388 1393
41. M.E. Sughrue, M.J. Rutkowski, and D. Aranda Factors affecting outcome following treatment of patients with cavernous sinus meningiomas J Neurosurg 113 2010 1087 1092
42. A. Modha, and P.H. Gutin Diagnosis and treatment of atypical and anaplastic meningiomas: a review Neurosurgery 57 2005 538 550 [discussion 538-550]
43. E. Abry, I.O. Thomassen, and O.O. Salvesen The significance of Ki-67/MIB-1 labeling index in human meningiomas: a literature study Pathol Res Pract 206 2010 810 815
44. C.M. Abramovich, and R.A. Prayson MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors Hum Pathol 29 1998 1420 1427 (Pubitemid 28563974)
45. A. Maillo, P. Diaz, and A. Blanco Proportion of S-phase tumor cells measured by flow cytometry is an independent prognostic factor in meningioma tumors Cytometry 38 1999 118 123 (Pubitemid 29300336)
46. L. Maes, E. Lippens, and J.P. Kalala The hTERT-protein and Ki-67 labelling index in recurrent and non-recurrent meningiomas Cell Prolif 38 2005 3 12 (Pubitemid 40229263)
47. E. Cabuy, and L. de Ridder Telomerase activity and expression of telomerase reverse transcriptase correlated with cell proliferation in meningiomas and malignant brain tumors in vivo Virchows Arch 439 2001 176 184 (Pubitemid 32758911)
48. P. Leuraud, E. Dezamis, and L. Aguirre-Cruz Prognostic value of allelic losses and telomerase activity in meningiomas J Neurosurg 100 2004 303 309 (Pubitemid 38140235)
49. J.S. Smith, A. Lal, and M. Harmon-Smith Association between absence of epidermal growth factor receptor immunoreactivity and poor prognosis in patients with atypical meningioma J Neurosurg 106 2007 1034 1040 (Pubitemid 46871117)
50. A.G. Wernicke, A.P. Dicker, and M. Whiton Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma Radiat Oncol 5 2010 46
51. M.D. Johnson, A. Woodard, and P. Kim Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells J Neurosurg 94 2001 293 300 (Pubitemid 32799692)
52. S.Y. Yang, and G.M. Xu Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas J Clin Neurosci 8 Suppl. 1 2001 49 53
53. M.A. Moore Putting the neo into neoangiogenesis J Clin Invest 109 2002 313 315 (Pubitemid 34141804)
54. V. Barresi, and G. Tuccari Increased ratio of vascular endothelial growth factor to semaphorin3A is a negative prognostic factor in human meningiomas Neuropathology 30 2010 537 546
55. V. Barresi, S. Cerasoli, and G. Tuccari Correlative evidence that tumor cell-derived caveolin-1 mediates angiogenesis in meningiomas Neuropathology 28 2008 472 478
56. V. Barresi, S. Cerasoli, and E. Vitarelli Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas Acta Neuropathol 114 2007 147 156 (Pubitemid 47103525)
57. V. Barresi, E. Vitarelli, and S. Cerasoli Semaphorin3A immunohistochemical expression in human meningiomas: correlation with the microvessel density Virchows Arch 454 2009 563 571
58. M. Maxwell, T. Galanopoulos, and E.T. Hedley-Whyte Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products Int J Cancer 46 1990 16 21 (Pubitemid 20225781)
59. G. Nagashima, J. Asai, and R. Suzuki Different distribution of c-myc and MIB-1 positive cells in malignant meningiomas with reference to TGFs, PDGF, and PgR expression Brain Tumor Pathol 18 2001 1 5
60. J.L. Wang, M. Nister, and M. Hermansson Expression of PDGF beta-receptors in human meningioma cells Int J Cancer 46 1990 772 778
61. M. Kirsch, J.C. Wilson, and P. Black Platelet-derived growth factor in human brain tumors J Neurooncol 35 1997 289 301 (Pubitemid 27511132)
62. T. Todo, E.F. Adams, and R. Fahlbusch Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor J Neurosurg 84 1996 852 858 [discussion 858-859]
63. P.Y. Wen, W.K. Yung, and K.R. Lamborn Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08) Neuro Oncol 11 2009 853 860
64. V. Gupta, C.G. Samuleson, and S. Su Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition Neurosurg Focus 23 2007 E9
65. K.M. Cook, and W.D. Figg Angiogenesis inhibitors: current strategies and future prospects CA Cancer J Clin 60 2010 222 243
66. R.S. Kerbel Tumor angiogenesis N Engl J Med 358 2008 2039 2049 (Pubitemid 351656458)
67. S. Goutagny, E. Raymond, and O. Sterkers Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab Ann Oncol 22 2011 990 991
68. M.J. Puchner, V.H. Hans, and A. Harati Bevacizumab-induced regression of anaplastic meningioma Ann Oncol 21 2010 2445 2446
69. C.K. Goldman, S. Bharara, and C.A. Palmer Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression Neurosurgery 40 1997 1269 1277 (Pubitemid 27251680)
70. J. Provias, K. Claffey, and L. delAguila Meningiomas: role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema Neurosurgery 40 1997 1016 1026 (Pubitemid 27202686)
71. M.C. Chamberlain, and M.J. Glantz Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas Cancer 113 2008 2146 2151
72. S.E. Kaba, F. DeMonte, and J.M. Bruner The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B Neurosurgery 40 1997 271 275 (Pubitemid 27045087)
73. C. Muhr, O. Gudjonsson, and A. Lilja Meningioma treated with interferon-alpha, evaluated with [(11)C]-l-methionine positron emission tomography Clin Cancer Res 7 2001 2269 2276 (Pubitemid 32751624)
74. D.W. Hsu, J.T. Efird, and E.T. Hedley-Whyte Progesterone and estrogen receptors in meningiomas: prognostic considerations J Neurosurg 86 1997 113 120 (Pubitemid 27009982)
75. S.M. Grunberg, M.H. Weiss, and I.M. Spitz Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone J Neurosurg 74 1991 861 866
76. S.M. Grunberg, M.H. Weiss, and C.A. Russell Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma Cancer Invest 24 2006 727 733 (Pubitemid 44949876)
77. J.W. Goodwin, J. Crowley, and H.J. Eyre A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study J Neurooncol 15 1993 75 77 (Pubitemid 23049702)
78. I.E. McCutcheon, A. Flyvbjerg, and H. Hill Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice J Neurosurg 94 2001 487 492 (Pubitemid 32786030)
79. W.M. Drake, A.B. Grossman, and R.K. Hutson Effect of treatment with pegvisomant on meningioma growth in vivo Eur J Endocrinol 152 2005 161 162 (Pubitemid 40185465)
80. S. Arena, F. Barbieri, and S. Thellung Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity J Neurooncol 66 2004 155 166 (Pubitemid 38258370)
81. P. Cavalla, and D. Schiffer Neuroendocrine tumors in the brain Ann Oncol 12 Suppl. 2 2001 S131 S134 (Pubitemid 33069702)
82. M. Henze, A. Dimitrakopoulou-Strauss, and S. Milker-Zabel Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas J Nucl Med 46 2005 763 769
83. S. Klutmann, K.H. Bohuslavizki, and W. Brenner Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma J Nucl Med 39 1998 1913 1917 (Pubitemid 28518893)
84. P.P. Garcia-Luna, F. Relimpio, and A. Pumar Clinical use of octreotide in unresectable meningiomas. A report of three cases J Neurosurg Sci 37 1993 237 241 (Pubitemid 24199309)
85. C. Bruns, I. Lewis, and U. Briner SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile Eur J Endocrinol 146 2002 707 716 (Pubitemid 34552506)